Updated:
TransMedics
TransMedics holds the only FDA-approved warm-perfusion platform for lung, heart, and liver transplants, replacing cold storage with its Organ Care System.
TransMedics
TransMedics operates from Andover, Massachusetts, with a platform built around the Organ Care System (OCS) — a portable perfusion device that maintains donor organs in a near-physiologic state outside the body. The technology spans lungs, hearts, and livers, each receiving distinct FDA premarket approval. The firm subsequently layered on the National OCS Program (NOP), a clinical service and logistics network that delivers the technology alongside dedicated transplant surgeons and perfusionists to hospitals, aiming to remove the operational friction of adoption. TransMedics addresses three organ-specific transplant workflows with OCS Lung, OCS Heart, and OCS Liver. The heart indication expanded materially when FDA approved OCS Heart for donation after circulatory death (DCD) donors, a pool previously largely untapped in the US. Alongside the technology, the NOP functions as an outsourced transplant retrieval service — TransMedics-employed teams fly to donor hospitals, recover organs onto OCS, and return them to the transplanting center. This effectively converts a fixed, center-bound surgical event into a dispatched field capability, concentrating case volume for hospitals without keeping full retrieval teams on standby. As of May 2024, TransMedics had not publicly disclosed AUM or an investment vehicle structure; public filings and the firm’s website position it strictly as a commercial medical device and service company with the OCS and NOP as its sole operating lines. The firm lists its corporate headquarters on Minuteman Road in Andover, with no additional international offices advertised. No named principals, professional headcount, or adjacent philanthropic vehicles were identifiable from primary sources. TransMedics’ structural differentiator lies in its regulatory exclusivity. The OCS remains the only warm-perfusion platform with US approval across three major solid organs, creating a competitive vacuum that allows the NOP to train transplant centers on a single-technology ecosystem. This vertical integration — device plus clinical service — means the firm not only supplies the hardware but also shapes the clinical protocol, a model rare among medical-device manufacturers.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Andover
Corporate office
200 Minuteman Road, Suite 302, Andover, MA 01810, United States
Sector focus
Frequently asked questions
How does TransMedics generate revenue?
TransMedics generates revenue through the sale and placement of Organ Care System (OCS) consoles and single-use perfusion sets for lung, heart, and liver transplants, and through its National OCS Program (NOP), which charges transplant centers a service fee for organ retrieval and management. As of its most recent public disclosures, these two lines constitute the entirety of reported operations.
What regulatory approvals does the Organ Care System hold?
The OCS holds FDA premarket approval for lung, heart, and liver indications. The heart indication includes both donation after brain death (DBD) and donation after circulatory death (DCD) donors, the latter approved following a supplemental PMA. No other warm-perfusion platform holds an equivalent breadth of US transplant approvals.
What is the National OCS Program (NOP)?
The NOP is TransMedics’ clinical service arm that deploys company-employed transplant surgeons and perfusionists to donor hospitals. They recover organs, place them on the OCS, and transport them to the recipient center, allowing hospitals to accept more organs without expanding their own retrieval staffing or logistics capacity.
Does TransMedics invest in healthcare companies or manage third-party capital?
There is no publicly available evidence that TransMedics operates an investment fund, manages outside capital, or functions as a family office. All primary-source materials from the firm describe a commercial medical-device and clinical-services business.
How does the OCS change the organ-transplant cold-ischemia constraint?
Standard cold storage stops metabolism to buy time, but the clock begins degrading tissue immediately. The OCS keeps the organ warm, perfused with oxygenated blood, and metabolically active, which extends the viable out-of-body window and lets surgeons assess organ function before transplant — a shift from a static preservation model to an active organ-management one.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: